The global Acute Ischemic Stroke (AIS) Market is estimated to be valued at US$ 8,517.0 million in 2021 and is expected to exhibit a CAGR of 4.0% over the forecast period 2021-2028, as highlighted in a new report published by Coherent Market Insights. AIS refers to a sudden lack of blood flow to the brain due to a blockage in one of the arteries, leading to neurological damage and potentially life-threatening complications. The market offers various products and treatments aimed at mitigating the impact of AIS, including thrombolytic agents and mechanical thrombectomy devices. These products have the potential to significantly improve patient outcomes by restoring blood flow to the brain and minimizing long-term disabilities associated with AIS.
Market key trends:
One key trend in the AIS market is the growing adoption of telemedicine and telestroke services. Telemedicine enables quick access to specialized stroke care, allowing healthcare professionals to remotely diagnose and treat patients with AIS. With the advancement in digital health technologies and improved connectivity, telestroke services have become more accessible, particularly in remote and underserved areas. The use of telestroke services can significantly reduce the time to treatment initiation, leading to better outcomes and increased chances of survival for AIS patients. Moreover, telemedicine platforms facilitate real-time consultations with stroke specialists, enabling timely decisions on thrombolysis and other therapies, further improving patient care in AIS.
The acute ischemic stroke (AIS) market can be segmented based on treatment type, end-user, and region. In terms of treatment type, the market is dominated by thrombolytic drugs, which are used to dissolve blood clots and restore blood flow to the brain. Thrombolytic drugs have proven to be highly effective in treating AIS and are widely prescribed by healthcare providers. Other treatment options, such as mechanical thrombectomy and antiplatelet drugs, also contribute to the market growth but to a lesser extent.
In terms of end-users, hospitals and clinics account for the largest share in the AIS market. This can be attributed to the availability of advanced medical infrastructure and skilled healthcare professionals in these settings. Moreover, hospitals are equipped with the necessary facilities to provide emergency care to stroke patients, including advanced imaging technology and specialized stroke units.
The Global Acute Ischemic Stroke (AIS) Market Demand is expected to witness high growth, exhibiting a CAGR of 4.0% over the forecast period. This growth can be attributed to several factors. Firstly, there is a growing incidence of AIS worldwide due to factors such as sedentary lifestyles, unhealthy eating habits, and the aging population. This has led to an increased demand for effective treatment options.
Regionally, North America dominates the AIS market in terms of both market size and growth rate. The region’s dominance can be attributed to factors such as well-established healthcare infrastructure, high healthcare expenditure, and increasing awareness about stroke management and treatment options. Furthermore, the presence of key market players in the region, such as F. Hoffmann-La Roche AG, Boehringer Ingelheim, and Pfizer Inc., contributes to the region’s market dominance.
Key players operating in the AIS market include F. Hoffmann-La Roche AG, Boehringer Ingelheim, Bayer AG, Pfizer Inc., Biogen, Daiichi Sankyo, Bristol-Myers Squibb, Johnson & Johnson, AstraZeneca, SanBio, and Athersys Inc. These companies are actively involved in research and development activities to introduce innovative treatment options and improve patient outcomes. Moreover, strategic collaborations, mergers, and acquisitions are also observed among key players to strengthen their market position and expand their product portfolio.